Exozymes Inc. has announced a strategic focus on the pharmaceutical and nutraceutical markets, aiming to leverage its AI-enhanced, cell-free exozyme platform in sectors identified for their high value, regulatory structure, and technical barriers to entry. The company plans to concentrate technology and business development efforts on markets with limited current access, attractive margin profiles, strong intellectual property protection, and long-term commercial durability. Exozymes intends to allocate resources to areas with defined regulatory pathways and durable demand, as part of its efforts to drive platform leverage and long-term value creation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1135665) on February 10, 2026, and is solely responsible for the information contained therein.